| First Author | Iwanowycz S | Year | 2021 |
| Journal | JCI Insight | Volume | 6 |
| Issue | 17 | PubMed ID | 34283809 |
| Mgi Jnum | J:312388 | Mgi Id | MGI:6787395 |
| Doi | 10.1172/jci.insight.145885 | Citation | Iwanowycz S, et al. (2021) Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors. JCI Insight 6(17) |
| abstractText | Type 2 DCs (DC2s) comprise the majority of conventional DCs within most tumors; however, little is known about their ability to initiate and sustain antitumor immunity, as most studies have focused on antigen cross-presenting DC1s. Here, we report that DC2 infiltration identified by analysis of multiple human cancer data sets showed a significant correlation with survival across multiple human cancers, with the benefit being seen in tumors resistant to cytotoxic T cell control. Characterization of DC subtype infiltration into an immunotherapy-resistant model of breast cancer revealed that impairment of DC1s through 2 unique models resulted in enhanced DC2 functionality and improved tumor control. BATF3 deficiency depleted intratumoral DC1s, which led to increased DC2 lymph node migration and CD4+ T cell activation. Enhancing DC2 stimulatory potential by genetic deletion of Hsp90b1 (encoding molecular chaperon GP96) led to a similar enhancement of T cell immunity and improved survival in a spontaneous breast cancer model. These data highlight the therapeutic and prognostic potential of DC2s within checkpoint blockade-resistant tumors. |
